How many 8-K filings has Moonlake Immunotherapeutics filed?

Moonlake Immunotherapeutics (MLTX) has 12 8-K (Current Event Report) filings on record, spanning Feb 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Moonlake Immunotherapeutics 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Moonlake Immunotherapeutics 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Moonlake Immunotherapeutics (MLTX) — 8-K Filings

All 8-K filings from Moonlake Immunotherapeutics. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

8-K Filing — May 11, 2026
MoonLake Immunotherapeutics Files 8-K for Material Agreement — Nov 5, 2025 Risk: low
On November 5, 2025, MoonLake Immunotherapeutics filed an 8-K report detailing a material definitive agreement. The company, formerly known as Helix Acquisition
MoonLake Immunotherapeutics Files 8-K — Sep 29, 2025 Risk: low
On September 29, 2025, MoonLake Immunotherapeutics filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no sp
MoonLake Immunotherapeutics Files 8-K on Shareholder Vote Matters — Jun 6, 2025 Risk: medium
MoonLake Immunotherapeutics filed an 8-K on June 6, 2025, reporting on a submission of matters to a vote of security holders. The filing indicates a change in t
MoonLake to Acquire Elevate Bio — Apr 29, 2025 Risk: medium
MoonLake Immunotherapeutics announced on April 29, 2025, that it has entered into a definitive agreement to acquire the privately held company, Elevate Bio, LLC
MoonLake Immunotherapeutics Files 8-K: Material Agreement — Apr 3, 2025 Risk: medium
MoonLake Immunotherapeutics entered into a material definitive agreement on March 31, 2025. This agreement constitutes a direct financial obligation or an oblig
MoonLake Immunotherapeutics Appoints New Officers and Directors — Dec 18, 2024 Risk: low
MoonLake Immunotherapeutics announced on December 12, 2024, the appointment of Dr. Oliver Schuh as Chief Medical Officer and Dr. Christian Schetter as Chief Sci
MoonLake to Acquire Remaining 49% of Subsidiary — Sep 11, 2024 Risk: medium
MoonLake Immunotherapeutics announced on September 11, 2024, that it has entered into a definitive agreement to acquire the remaining 49% stake in its subsidiar
MoonLake Immunotherapeutics Files 8-K — Jun 10, 2024 Risk: low
MoonLake Immunotherapeutics filed an 8-K on June 10, 2024, reporting on various corporate events. The filing includes information related to Regulation FD discl
MoonLake Immunotherapeutics Files 8-K on Shareholder Vote — Jun 6, 2024 Risk: low
MoonLake Immunotherapeutics filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The filing details the c
MoonLake Immunotherapeutics Closes $100M Public Offering — Mar 11, 2024 Risk: medium
On March 10, 2024, MoonLake Immunotherapeutics announced the closing of its previously announced underwritten public offering. The company successfully raised a
MoonLake Immunotherapeutics Files 8-K on Feb 26 — Feb 26, 2024 Risk: low
MoonLake Immunotherapeutics filed an 8-K on February 26, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a curr

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX